Study: NCT04381936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir-Ritonavir
Description: Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent plasma
Description: Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Description: Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic neutralising antibodies
Description: Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Corticosteroid
Description: Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotrovimab
Description: UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Molnupiravir
Description: Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid
Description: UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil
Description: Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose corticosteroids: Dexamethasone
Description: Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose corticosteroids: Dexamethasone
Description: ≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)